Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Chimeric receives $3.06m R&D tax incentive (ASX:CHM)

Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), a clinical stage cell therapy company and an Australian leader in cell therapy, is pleased announce it has recei...read more

Carbonxt Group - Update to Appendix 4C and Quarterly Activities Report (ASX:CG1)

Carbonxt Group Limited (ASX:CG1) provides an update to the Appendix 4C and Quarterly Activities Report which was released to the ASX on 31 January 2023. The attached Appendix 4C and Quarterly Activi...read more

Carbonxt Group - December 2022 Quarterly Activities Report (ASX:CG1)

Highlights -- Quarterly customer receipts of A$3.9m – a decrease of 24% compared to prior quarter. The decline was anticipated and was due primarily to planned downtime to install new equip...read more

Chimeric Therapeutics - Quarterly Activities/Appendix 4C Cash Flow Report (ASX:CHM)

Highlights -- Completion of dosing in 3rd dose cohort in CHM 1101 (CLTX CAR T) clinical trial -- Sponsored research agreement with Case Western University to advance Core NK Portfolio -- Exclus...read more

Careteq - Q2-FY23 APPENDIX 4C (ASX:CTQ)

To view the Appendix 4C, download the attached PDF.

Careteq - Q2-FY23 ACTIVITIES REPORT (ASX:CTQ)

ACTIVITIES REPORT AND APPENDIX 4C: SIGNIFICANT SALES CONVERSION & SALES PIPELINE EXPANSION Significant increase in contracts won and expansion of sales pipeline for both Sofihub&n...read more

Chimeric Therapeutics - Follow up period completed for 3rd cohort in CHM 1101 trial (ASX:CHM)

3rd dose cohort in the CHM 1101 (CLTX CAR T) cell therapy phase 1 clinical trial completed All patients have advanced past the 28-day safety follow up period without experiencing&n...read more

Chimeric Therapeutics - Dosing complete in 3rd cohort of CHM 1101 (CLTX CAR T) trial (ASX:CHM)

-- Dosing in the 3rd dose cohort in the CHM 1101 (CLTX CAR T) cell therapy Phase 1 clinical trial has been completed at City of Hope -- This 3rd dose cohort received CHM 1101 (CLTX CAR T) cells at ...read more

Careteq receives $947K R&D Tax Refund (ASX:CTQ)

Careteq Limited (ASX: CTQ, “Careteq” or the “Group”) is pleased to announce that its cash position has been bolstered by the receipt of $947,123 from the Australian Taxation ...read more

Chimeric Therapeutics - Exclusive license agreement with CWRU for CORE-NK platform (ASX:CHM)

Exclusive global license for CORE NK platform (CHM 0201) executed with Case Western Reserve University in Ohio Initial Phase 1 clinical trial results of the CORE NK platfo...read more

Application for quotation of securities - CG1 (ASX:CG1)

To view the application, download the attached PDF.

Carbonxt Group - Share Purchase Plan Share Issue (ASX:CG1)

Following the announcement earlier today regarding the results of the Share Purchase Plan (SPP) Carbonxt Group Ltd (“Carbonxt” or the “Company”) (ASX: CG1) provides an update...read more

Carbonxt Group - Application for quotation of securities - CG1 (ASX:CG1)

To view the application for quotation of securities , download the attached PDF.

Carbonxt Group - Share Purchase Plan Closes Oversubscribed Raising $1.58m (ASX:CG1)

Carbonxt Group Ltd (“Carbonxt” or the “Company”) (ASX: CG1) is pleased to report that it has enjoyed strong shareholder support for the Share Purchase Plan (SPP) announc...read more

Carbonxt Group - Appendix 4C (ASX:CG1)

To view the appendix, download the attached PDF.

Viewing: 76 - 90 of 200 Previous | Next